Compare DXR & JFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DXR | JFU |
|---|---|---|
| Founded | 1970 | 2006 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 59.2M |
| IPO Year | N/A | 2019 |
| Metric | DXR | JFU |
|---|---|---|
| Price | $12.80 | $6.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 7.4K | ★ 9.4K |
| Earning Date | 02-27-2026 | 12-09-2022 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.46 | ★ 3110.57 |
| EPS | 0.36 | ★ 3.04 |
| Revenue | $66,306.00 | ★ $44,573,690.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.27 | ★ $1.97 |
| Revenue Growth | N/A | ★ 8.19 |
| 52 Week Low | $6.55 | $1.01 |
| 52 Week High | $14.76 | $9.48 |
| Indicator | DXR | JFU |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 43.77 |
| Support Level | $11.87 | $5.68 |
| Resistance Level | $12.90 | $6.22 |
| Average True Range (ATR) | 0.63 | 0.58 |
| MACD | -0.22 | -0.11 |
| Stochastic Oscillator | 12.00 | 14.10 |
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.